Why ENDRA Life Sciences (NDRA) Stock Is Up 140%
Portfolio Pulse from Henry Khederian
ENDRA Life Sciences (NASDAQ:NDRA) shares surged by 94.6% after announcing a post-market clinical study of its TAEUS liver system at LMU University Hospital in Munich. The study aims to compare TAEUS' liver fat measurement capabilities with the MRI-PDFF test, potentially enhancing its clinical data portfolio and supporting its FDA De Novo submission by mid-2025.
October 22, 2024 | 4:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
ENDRA Life Sciences' stock rose significantly due to the initiation of a clinical study for its TAEUS liver system, which could enhance its clinical data and support an FDA submission.
The announcement of a clinical study in Germany for the TAEUS liver system is a significant development for ENDRA Life Sciences. This study could provide critical data to support their FDA De Novo submission, potentially increasing the product's marketability and acceptance. The stock's sharp rise reflects investor optimism about these prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100